Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE American: NNVC) closed a registered direct offering and concurrent private placement on November 12, 2025, raising approximately $6.0 million by selling 3,571,429 shares at $1.68 per share to a single healthcare institutional investor.

Concurrently, the company sold Series A warrants to purchase up to 3,571,429 shares at a $1.75 exercise price (exercisable after 6 months; 2-year term) and Series B warrants to purchase up to 3,571,429 shares at a $2.00 exercise price (exercisable after 6 months; 5.5-year term). Series B exercise price was ~20% premium to the Nov 10, 2025 closing price. Net proceeds will be used for working capital and general corporate purposes.

NanoViricides (NYSE American: NNVC) announced a registered direct offering of 3,571,429 shares at $1.68 per share for gross proceeds of approximately $6.0 million, expected to close on or about November 12, 2025, subject to customary conditions.

Concurrently the company will issue Series A warrants (exercise $1.75, exercisable after 6 months, 2‑year term) and Series B warrants (exercise $2.00, exercisable after 6 months, 5.5‑year term) to purchase up to 3,571,429 shares each. The Series B exercise price is ~20% premium to the Nov 10, 2025 closing price. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.

NanoViricides (NYSE American: NNVC) announced on November 10, 2025 that the Democratic Republic of Congo regulatory agency ACOREP has approved the start of a Phase II clinical trial of NV-387 for treatment of MPox (hMPXV), subject to filing certain final documents and translations.

The company previously received Ethics Committee (CNES) clearance in May 2025 and is preparing English and French certified clinical trial application materials. NV-387 has reported broad preclinical antiviral activity across multiple lethal animal models, and the program targets MPox as well as other respiratory and systemic viral infections.

NanoViricides (NYSE:NNVC) will hold its Annual Shareholders Meeting on November 8, 2025 at 10:00 am at Hampton Inn & Suites Stamford, CT. Management will review progress toward clinical development, including completion of the Clinical Trial Application and plans to initiate a Phase II trial of NV-387 for MPox in the Democratic Republic of Congo. NV-387 completed a Phase I trial with a described safety and tolerability profile and showed efficacy in animal orthopoxvirus models versus tecovirimat.

The release also summarises MPox risks (recent US Clade I cases, case fatality ranges) and contrasts NV-387 with existing countermeasures and their limitations.

NanoViricides (NYSE American: NNVC) will present at the Spartan Capital Investor Conference in New York City on November 3, 2025 at 09:45am ET. Anil R. Diwan, PhD, President and Executive Chairman, will provide an update on the company, its drug pipeline and nanoviricide platform technologies available for licensing.

Key disclosed items include: NV-387 in Phase II (planned MPox trial in Democratic Republic of Congo) and development for RSV, influenza, COVID/Long COVID, and other respiratory indications; clinical-ready NV-HHV-1 (pan-herpesvirus) and NV-HIV-1; and platform capabilities for drug encapsulation, oral delivery, and targeted "zip-code" delivery. The release reiterates forward-looking risks and uncertainty about timelines, regulatory approvals, and development outcomes.

NanoViricides (NYSE American: NNVC) CEO Dr Anil Diwan told Proactive (Oct 29, 2025) that lead drug NV-387 showed potent anti-measles activity in cell culture and a humanized animal model and protected lung tissue.

In a lethal measles model, NV-387 extended survival by 130% (from 7.4 days to 17 days). NV-387 completed Phase I with no reportable adverse events and is formulated as oral gummies. The company said it can support emergency use or physician-initiated INDs and is advancing NV-387 into Phase II for MPox.

NanoViricides (NYSE American: NNVC) will present at PODD 2025 in Boston on October 27, 2025 at 03:00 pm; Anil R. Diwan, PhD, will update the company, its drug pipeline, and licensing opportunities.

The company says lead candidate NV-387 is moving into Phase II for MPox in the Democratic Republic of Congo and a separate Phase II for respiratory ARI/SARI is being planned. NV-387 reportedly showed complete cure in an RSV animal study and activity versus Influenza A, coronaviruses, measles, and orthopox models. The company cites a total addressable market in excess of $10 billion. NanoViricides also describes clinical-ready candidates NV-HHV-1 and NV-HIV-1 and platform capabilities for oral delivery and targeted encapsulation.

NanoViricides (NYSE American: NNVC) announced that its lead candidate NV-387 showed strong antiviral activity against Measles in cell culture and a humanized lethal mouse model, increasing median survival to 17 days from 7.4 days (a 130% increase).

NV-387 treatment correlated with slower disease progression, reduced lung plaques, and lower lung infiltration by lymphocytes and neutrophils. NV-387 completed Phase I with no reportable adverse events and is available as an oral gummy formulation. The company said Measles-specific development is not cost-effective and intends to seek non-dilutive grants while advancing NV-387 for multiple respiratory viruses.

NanoViricides (NYSE American: NNVC) announced that its lead drug NV-387 showed strong activity against measles in a humanized animal model and can be made available now for emergency use via Physician Investigator Initiated INDs.

Key data: survival increased to 17 days vs 7.4 days (≈130% increase) in treated animals, dose-dependent survival, and no signs of toxicity. NV-387 completed a Phase I study in healthy subjects with no reported adverse events. The drug is manufactured under GMP in the USA and is formulated as oral gummies for easy administration.